Cyclacel Pharmaceuticals, Inc. reported the updated mean survival data of its ongoing multi-center study on Sapacitabine conducted at the University of Texas MD Anderson Cancer Center. The company’s lead product candidate – sapacitabine –has been showing promising results in its phase 2 randomized trials. The mean survival rate in all 63 treated patients so far is 9 months, or 259 days.
http://bionews-tx.com/news/2013/05/01/cyclacel-reports-updated-phase-2-survival-data-of-sapacitabine-for-mds-conducted-at-md-anderson/
Showing posts with label MDS. Show all posts
Showing posts with label MDS. Show all posts
Wednesday, May 1, 2013
Tuesday, April 16, 2013
MD Anderson Researchers Discover RAS Gene Mutations Are Uncommon In MDS And Do Not Affect Prognosis
Read about how MD Anderson Researchers Discover RAS Gene Mutations Are Uncommon In MDS And Do Not Affect Prognosis.
http://bionews-tx.com/news/2013/04/16/md-anderson-researchers-discover-ras-gene-mutations-are-uncommon-in-mds-and-do-not-affect-prognosis/
Subscribe to:
Posts (Atom)